Abstract: Prion infectivity adsorbed onto substrates (for example, chromatographic columns used to fractionate blood plasma) is removed by treatment with 2M sodium chloride. Optionally, the substrate is further washed with 0.1 M sodium hydroxide.

Abstract: Liquid pharmaceutical compositions stored in glass containers, (particularly of blood plasma proteins such as albumin) having a shelf-life in excess of 18 months; over which time the aluminium content is maintained below 200 micrograms per litre. This is achieved by silicone-coating the glass container. Also the particles/ml post-autoclave and post-pasteurisation are kept to low levels.

Abstract: Liquid compositions for intravenous administration that comprise an aqueous solution of immunoglobulin and methods of preparing such compositions are disclosed. The solution has a pH in the range of 5.0 to 5.8 and an ionic strength is the range 0.02 to 0.25. The liquid compositions are formulated so as to be stable upon storage such that the immunoglobulin does not substantially aggregate nor degrade and maintains acceptable levels of anti-complementary activity, PKA activity and kallikrein activity during storage for an extended period at a temperature in the range of 4° C. to 25° C.

Abstract: A lyophilized fibrinogen is produced which is subjected to a severe terminal virucidal heat treatment in order to inactivate viruses present, while retaining desirable biological properties. In particular the lyophilized fibrinogen has a solubility in water or other aqueous solution to 40 g/l in less than 20 minutes at 20.degree. C., and a clotting time of less than 10 seconds when exposed to at least 200 U/ml thrombin. The product may be heat treated at 80.degree. C. for 72 hours up to 100.degree. C. for 10 hours depending on formulation and water content. In the production process cryoprecipitate is washed with polyethylene glycol solution at 4 to 10.degree. C. and pH 6.8 to 8 at low ionic strength, prior to two-stage freeze drying.